<DOC>
	<DOCNO>NCT01079702</DOCNO>
	<brief_summary>In investigator study investigator combine everolimus , administrate twice daily fix total dose 10 mg continuously capecitabine administer bid 14 day follow 7 day rest . In study , capecitabine dose escalate .</brief_summary>
	<brief_title>Everolimus Capecitabine Patients With Advanced Malignancy</brief_title>
	<detailed_description>The result form preclinical study suggest mTOR inhibitor promise drug treatment various type cancer . Everolimus seem attractive mTOR inhibitor favourable pharmacokinetic profile possibility oral administration . Based preclinical finding , mTOR inhibitor may efficacious use rational combination cancer regiment like cytostatic drug . Indeed , several multiagent combination investigate clinical trial moment , result promise . In study combine everolimus , administrate twice daily fix total dose 10 mg continuously capecitabine administer bid 14 day follow 7 day rest . In study , capecitabine dose escalate . The first dose level capecitabine 500 mg/m2 twice daily . Three patient enrol per dose level , start dose level 1 . If one 3 patient develops dose-limiting toxicity dose level , 3 patient start dose level . If 2 6 patient develop DLT , dose escalation perform . The MTD consider dose give previous low level . No intrapatient dose escalation apply . Once MTD capecitabine establish , phase II part study start 25 patient various malignancy enrol evaluate efficacy feasibility combination everolimus capecitabine .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients histological cytological confirm malignancy Measurable lesion accord RECIST criterion ( phase II part study ) ECOG / WHO performance status 02 Age ≥ 18 year Life expectancy least 3 month Minimal acceptable safety laboratory value define : WBC ≥ 3.0 x 109 /L Platelet count ≥ 100 x 109 /L Hepatic function define serum bilirubin ≤ 1.5 x ULN , ALT AST ≤ 2.5 x ULN , case liver metastases ≤ 5 x ULN Renal function define creatinine &lt; 150μmol/L Able willing give write informed consent Able swallow retain oral medication Able willing undergo blood sample pharmacokinetic pharmacogenetic analysis Mentally , physically geographically able undergo treatment follow . Patients known alcoholism , drug addiction and/or psychotic disorder history suitable adequate follow Women pregnant breast feed Women childbearing potential refuse use reliable contraceptive method throughout study Serious concomitant systemic disorder would compromise safety patient , discretion investigator Any medical condition would interfere study procedure and/or decrease safety protocol treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>